Why trust GLP Chart.
No program buys its way up this chart. We set the rank order before any money changes hands, and everything on this page is checkable.
Scoring and the team
Every program gets the same five pillars: pricing, cancellation, onboarding, medication options, and member feedback. One 0 to 10 rubric, applied the same way to all of them. The full definitions, data sources, and verification steps sit on the methodology page. The rubric has not changed since April 1, 2026.
One person decides which programs make the chart and how they score. That person is John Samaras, the editor, working on this full time from Austin, Texas. See his LinkedIn or his full bio.
Every clinical claim traces to a published registration trial or the approved prescribing information. This is not clinician-authored medical advice.
Paid placements: zero
No program can pay to move up this chart. We lock the rank order before any commercial relationship exists. Where a Visit link earns us a commission, we mark it sponsored per FTC and Google rules. The full GLP Chart Pledge lays out all seven editorial commitments.
How we make money
Some Visit links earn us an affiliate commission. That commission never moves a score or a rank. No program pays to be listed. We do not sell placement, sponsored content, or email-list rentals. The full breakdown is on the About page.
Independence
John Samaras owns and operates GLP Chart as an independent editorial operator in Austin, Texas. It runs on no outside investment and holds no equity or preferred partnership with any program on the chart. No program gets to approve or preview our content before it publishes. We take nothing from the programs we cover or from any GLP-1 manufacturer: no gifts, free samples, sponsored trips, consulting fees, or speaking honoraria.
Programs we decline to cover
Some programs never make the chart. We do not list programs that:
- Refuse to publish their pricing publicly
- Refuse to disclose their compounding pharmacy partner
- Make claims about unapproved peptides (AOD-9604, BPC-157, MOTS-c, etc.)
- Use deceptive comparison advertising against named competitors
- Have outstanding state pharmacy-board sanctions or unresolved FDA actions over product safety or quality (a warning letter over marketing claims is recorded on the program page)
- Operate without a state-licensed prescribing clinician for the patient's state of residence
Declining these programs costs us real affiliate revenue. We do it anyway, because the chart is only worth something if it leaves out the programs we would not recommend to family.
Disclosed conflicts
Right now there is nothing to disclose. John holds no job with any program on the chart, no consulting role with any pharmaceutical manufacturer, and no investment, public or private, in any company we cover. If that ever changes (new consulting work, an investment, a job), we post it here within 30 days and review any coverage it touches.
What programs publish
Every maintenance price on the chart is the number the program publishes, confirmed within the last 30 days against its own pricing pages. Not a marketing claim. Not an advertised teaser. We read the maintenance-dose figure the program posts, and when a site blocks automated access we confirm it by searching the program's own materials. Every price cites its published source. When a price moves, it shows up in the What moved this week callout in the newsroom and gets a row in the corrections log.
Corrections log
When we get something wrong, we say so publicly, with a date. We never quietly edit a published score or claim. The full log ships with every Monday price check. The recent ones:
Found a problem?
Email corrections@glpchart.com. We answer within one business day. If a published claim is wrong, the fix goes up in the next Monday price check, and we credit you by name if you let us.
We email you when a price moves.
Every Monday we check every program against its published pricing. When a price moves or a lock-in clause shows up, you hear about it first.
